Scholarlink

<p><i>Helicobacter pylori</i> (<i>H. pylori</i>) is the most common carcinogenic pathogen globally and the leading cause of gastric cancer. Here, we develop a reinforcement learning-based AI Clinician system to personalise treatment selection and evaluate its ability to improve eradication success compared to clinician-prescribed therapies. The model is trained and internally validated on 38,049 patients from the retrospective European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg), using independent state&#xa0;deep Q-learning (isDQN) to recommend optimal therapies based on patient characteristics such as age, sex, antibiotic allergies, country, and pre-treatment indication. In internal validation using real-world Hp-EuReg data, AI-recommended therapies achieve a 94.1% success rate (95% CI: 93.2–95.0%) versus 88.1% (95% CI: 87.7–88.4%) for clinician-prescribed therapies not aligned with AI suggestions—an improvement of 6.0%. Results are replicated in an external validation cohort (<i>n</i> = 7186), confirming generalisability. The AI system identifies optimal treatment strategies in key subgroups: 65% (<i>n</i> = 24,923) are recommended bismuth-based therapies, and 15% (<i>n</i> = 5898) non-bismuth quadruple therapies. Random forest modelling identifies region and concurrent medications as patient-specific drivers of AI recommendations. With nearly half the global population likely to contract <i>H. pylori</i>, this approach lays the foundation for future prospective clinical validation and shows the potential of AI to support clinical decision-making, enhance outcomes, and reduce gastric cancer burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月14日

查看全文
  • Kyle Higgins,
  • Olga P. Nyssen,
  • Joshua Southern,
  • Ivan Laponogov,
  • Ana Miralles Marco,
  • Manuel Cabeza-Segura,
  • Elena Jiménez Martí,
  • Josefa Castillo,
  • Mārcis Leja,
  • Inese Poļaka,
  • Fatima Carneiro,
  • Ceu Figueiredo,
  • Rui M. Ferreira,
  • Rita Barros,
  • Leticia Moreira,
  • Miriam Cuatrecasas,
  • Gloria Fernandez-Esparrach,
  • Tamara Matysiak-Budnik,
  • Jerome Martin,
  • Laimas Jonaitis,
  • Juozas Kupčinskas,
  • Paulius Jonaitis,
  • Mário Dinis-Ribeiro,
  • Miguel Coimbra,
  • Ana Carina Pereira,
  • Filipa Fontes,
  • Manon C. W. Spaander,
  • Judith Honing,
  • Stefano Sedola,
  • Junior Andrea Pescino,
  • Zorana Maravic,
  • Ana Martins,
  • Dennis Veselkov,
  • Javier P. Gisbert,
  • Tania Fleitas Kanonnikoff,
  • Kirill Veselkov

摘要

Helicobacter pylori (H. pylori) is the most common carcinogenic pathogen globally and the leading cause of gastric cancer. Here, we develop a reinforcement learning-based AI Clinician system to personalise treatment selection and evaluate its ability to improve eradication success compared to clinician-prescribed therapies. The model is trained and internally validated on 38,049 patients from the retrospective European Registry on Helicobacter pylori Management (Hp-EuReg), using independent state deep Q-learning (isDQN) to recommend optimal therapies based on patient characteristics such as age, sex, antibiotic allergies, country, and pre-treatment indication. In internal validation using real-world Hp-EuReg data, AI-recommended therapies achieve a 94.1% success rate (95% CI: 93.2–95.0%) versus 88.1% (95% CI: 87.7–88.4%) for clinician-prescribed therapies not aligned with AI suggestions—an improvement of 6.0%. Results are replicated in an external validation cohort (n = 7186), confirming generalisability. The AI system identifies optimal treatment strategies in key subgroups: 65% (n = 24,923) are recommended bismuth-based therapies, and 15% (n = 5898) non-bismuth quadruple therapies. Random forest modelling identifies region and concurrent medications as patient-specific drivers of AI recommendations. With nearly half the global population likely to contract H. pylori, this approach lays the foundation for future prospective clinical validation and shows the potential of AI to support clinical decision-making, enhance outcomes, and reduce gastric cancer burden.